CN102015719A - 吡咯并三嗪激酶抑制剂 - Google Patents

吡咯并三嗪激酶抑制剂 Download PDF

Info

Publication number
CN102015719A
CN102015719A CN2009801164877A CN200980116487A CN102015719A CN 102015719 A CN102015719 A CN 102015719A CN 2009801164877 A CN2009801164877 A CN 2009801164877A CN 200980116487 A CN200980116487 A CN 200980116487A CN 102015719 A CN102015719 A CN 102015719A
Authority
CN
China
Prior art keywords
substituted
cancer
group
compounds
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801164877A
Other languages
English (en)
Chinese (zh)
Inventor
厄潘德·维拉帕蒂
多拉特雷·M·维亚斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102015719A publication Critical patent/CN102015719A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2009801164877A 2008-03-06 2009-03-04 吡咯并三嗪激酶抑制剂 Pending CN102015719A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3417108P 2008-03-06 2008-03-06
US61/034,171 2008-03-06
PCT/US2009/035975 WO2009111531A1 (en) 2008-03-06 2009-03-04 Pyrrolotriazine kinase inhibitors

Publications (1)

Publication Number Publication Date
CN102015719A true CN102015719A (zh) 2011-04-13

Family

ID=40578742

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801164877A Pending CN102015719A (zh) 2008-03-06 2009-03-04 吡咯并三嗪激酶抑制剂

Country Status (5)

Country Link
US (1) US8212031B2 (https=)
EP (1) EP2262806A1 (https=)
JP (1) JP2011513419A (https=)
CN (1) CN102015719A (https=)
WO (1) WO2009111531A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081783A1 (zh) * 2013-12-06 2015-06-11 江苏奥赛康药业股份有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
CN110950871A (zh) * 2019-12-25 2020-04-03 陕西师范大学 2-取代-4-芳氨基吡唑并三嗪衍生物及制备抗肿瘤药物的应用
WO2020073749A1 (zh) * 2018-10-10 2020-04-16 中国药科大学 吡咯并三嗪类化合物及其应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445676B2 (en) 2008-10-08 2013-05-21 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
PH12012500901A1 (en) 2009-11-05 2016-08-05 Rhizen Pharmaceuticals Sa Novel benzopyran kinase modulators
HRP20190128T1 (hr) 2011-05-04 2019-03-08 Rhizen Pharmaceuticals S.A. Novi spojevi kao modulatori protein kinaza
CN109970742A (zh) 2012-07-04 2019-07-05 理森制药股份公司 选择性PI3Kδ抑制剂
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
AU2023249795A1 (en) 2022-04-08 2024-10-17 Shy Therapeutics, Llc Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008596B1 (ru) * 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
HRP20140688T1 (hr) * 2006-07-07 2014-10-24 Bristol-Myers Squibb Company Inhibitori piroltriazin kinaze
US7531539B2 (en) * 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN101687874B (zh) 2007-04-18 2013-01-30 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
US8445676B2 (en) * 2008-10-08 2013-05-21 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081783A1 (zh) * 2013-12-06 2015-06-11 江苏奥赛康药业股份有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
WO2020073749A1 (zh) * 2018-10-10 2020-04-16 中国药科大学 吡咯并三嗪类化合物及其应用
CN110950871A (zh) * 2019-12-25 2020-04-03 陕西师范大学 2-取代-4-芳氨基吡唑并三嗪衍生物及制备抗肿瘤药物的应用
CN110950871B (zh) * 2019-12-25 2022-05-17 陕西师范大学 2-取代-4-芳氨基吡唑并三嗪衍生物及制备抗肿瘤药物的应用

Also Published As

Publication number Publication date
US8212031B2 (en) 2012-07-03
JP2011513419A (ja) 2011-04-28
EP2262806A1 (en) 2010-12-22
US20110003821A1 (en) 2011-01-06
WO2009111531A1 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
US8198438B2 (en) Pyrrolotriazine kinase inhibitors
JP5282091B2 (ja) トリアジンキナーゼ阻害剤
KR101443400B1 (ko) 피롤로트리아진 키나제 억제제
CN102015719A (zh) 吡咯并三嗪激酶抑制剂
US7514435B2 (en) Pyrrolotriazine kinase inhibitors
US8445676B2 (en) Pyrrolotriazine kinase inhibitors
CN101535312B (zh) 吡咯并三嗪激酶抑制剂
WO2009100375A1 (en) Substituted imidazopyridazines useful as kinase inhibitors
EP2049542A1 (en) Pyrrolotriazine kinase inhibitors
US7442700B2 (en) Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7851500B2 (en) Aminopyrazole kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110413